Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension

Jiegen Chen, Josepmaria Argemí, Gemma Òdena, Mingjiang Xu, Yan Cai, Veronica Massey, Austin R. Parrish, Rajanikanth Vadigepalli, José Altamirano, Joaquín Cabezas, Pere Ginès, Juan Caballería, Natasha T. Snider, Pau Sancho‐Bru, Shizuo Akira, Ivan Rusyn, Bin Gao, Ramón BatallerScientific 2020 · DOI

Abstract

Advanced fibrosis and portal hypertension are critical determinants of mortality in alcoholic hepatitis (AH). This study identifies Lipocalin 2 (LCN2) as a functional regulator of these processes. We found that hepatic LCN2 expression is markedly increased in AH patients, correlating with disease severity and portal pressure. Mechanistically, LCN2 promotes fibrosis and vasoconstriction through a HIF1A-EDN1 signaling axis. LCN2 knockout mice demonstrated significant protection against experimental liver fibrosis, suggesting LCN2 as a potential therapeutic target.

Introduction

Alcoholic hepatitis (AH) is a severe clinical syndrome characterized by acute liver failure and high short-term mortality. The prognosis is heavily influenced by the degree of liver fibrosis and the severity of portal hypertension—elevated blood pressure within the portal venous system. Despite their clinical importance, the molecular drivers of these pathologies in AH remain poorly understood, and current treatments like corticosteroids offer limited efficacy. This research investigates the role of Lipocalin 2 (LCN2), an innate immune protein, in the progression of AH.

Methods

The study utilized a translational approach combining human clinical data with experimental models:

  • Human Clinical Analysis: Liver biopsies and serum samples from the InTeam Consortium were analyzed. Gene expression was mapped using RNA-sequencing and microarrays (GEO: GSE130123, GSE130128).
  • Animal Models: $Lcn2^{-/-}$ (knockout) and wild-type mice were subjected to chronic $CCl_4$ exposure and an "ethanol plus binge" model to simulate liver injury and fibrosis.
  • In Vitro Mechanistic Studies: Human primary hepatocytes and Hepatic Stellate Cells (HSCs) were used to trace signaling pathways via LCN2 overexpression, siRNA knockdown, and ChIP-qPCR.

Results

LCN2 is Markedly Elevated in Alcoholic Hepatitis

Analysis of human liver tissue revealed that LCN2 expression is uniquely and significantly upregulated in AH compared to healthy controls, Hepatitis C (HCV), and cirrhosis. While LCN2 is typically restricted to immune cells in healthy livers, it is "reprogrammed" for mass production by hepatocytes in the context of AH.

Hepatic LCN2 expression is significantly elevated in patients with alcoholic hepatitis (AH) compared to controls and other liver diseases.

Correlation with Disease Severity and Portal Hypertension

Hepatic LCN2 levels showed strong positive correlations with clinical severity scores (MELD and ABIC). Crucially, LCN2 expression correlated with the Hepatic Venous Pressure Gradient (HVPG), a direct measure of portal hypertension, and with the expression of key fibrotic markers such as $COL1A1$ and $TIMP1$.

LCN2 expression correlates with portal hypertension (HVPG) and markers of fibrosis (COL1A1, TIMP1) in AH patients.

LCN2 Deficiency Protects Against Fibrosis

In experimental models, $Lcn2^{-/-}$ mice were significantly protected from liver fibrosis induced by $CCl_4$ or ethanol. These mice exhibited reduced collagen accumulation and lower expression of pro-fibrotic genes compared to wild-type controls. In vitro experiments confirmed that recombinant LCN2 directly stimulates collagen production in human Hepatic Stellate Cells.

Discussion

The study uncovers the LCN2-HIF1A-EDN1 molecular axis as a driver of liver pathology. LCN2 induces HIF1A, which in turn upregulates Endothelin 1 (EDN1), a potent vasoconstrictor that increases portal pressure. Simultaneously, LCN2 acts as a pro-fibrotic agent by activating stellate cells.

While mouse models do not perfectly replicate the full spectrum of human AH, the strong correlation in human tissue suggests LCN2 is a functional driver rather than a passive biomarker. As a secreted protein, LCN2 represents a promising "druggable" target for neutralizing therapies aimed at reducing fibrosis and managing portal hypertension in severe liver disease.

Summary updated

Abstract

Abstract Advanced fibrosis and portal hypertension influence short-term mortality. Lipocalin 2 (LCN2) regulates infection response and increases in liver injury. We explored the role of intrahepatic LCN2 in human alcoholic hepatitis (AH) with advanced fibrosis and portal hypertension and in experimental mouse fibrosis. We found hepatic LCN2 expression and serum LCN2 level markedly increased and correlated with disease severity and portal hypertension in patients with AH. In control human livers, LCN2 expressed exclusively in mononuclear cells, while its expression was markedly induced in AH livers, not only in mononuclear cells but also notably in hepatocytes. Lcn2 −/− mice were protected from liver fibrosis caused by either ethanol or CCl 4 exposure. Microarray analysis revealed downregulation of matrisome, cell cycle and immune related gene sets in Lcn2 −/− mice exposed to CCl 4 , along with decrease in Timp1 and Edn1 expression. Hepatic expression of COL1A1 , TIMP1 and key EDN1 system components were elevated in AH patients and correlated with hepatic LCN2 expressio n. In vitro , recombinant LCN2 induced COL1A1 expression. Overexpression of LCN2 increased HIF1A that in turn mediated EDN1 upregulation. LCN2 contributes to liver fibrosis and portal hypertension in AH and could represent a new therapeutic target.
BibTeX
@inproceedings{chen2020hepatic,
  author = {Jiegen Chen and Josepmaria Argemí and Gemma Òdena and Mingjiang Xu and Yan Cai and Veronica Massey and Austin R. Parrish and Rajanikanth Vadigepalli and José Altamirano and Joaquín Cabezas and Pere Ginès and Juan Caballería and Natasha T. Snider and Pau Sancho‐Bru and Shizuo Akira and Ivan Rusyn and Bin Gao and Ramón Bataller},
  title = {{Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension}},
  booktitle = {Scientific},
  year = {2020},
  doi = {10.1038/s41598-020-72172-7},
}
Figure